PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system.

Alfredo Papa, Silvio Danese

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

9 Citazioni (Scopus)


In both Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease (IBD), an increased risk of thrombotic events has been demonstrated. Pathogenesis of thrombosis is multifactorial as various primary coagulation system abnormalities other than acquired factors have been reported. The fibrinolytic system has been widely investigated in IBD. Most of the available data report an imbalance in fibrinolytic capacity with a tendency toward a hypofibrinolytic state. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 are fundamental inhibitors of the fibrinolytic process and are also considered to be acute-phase reactants. Recent studies have shown an imbalance of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor, suggesting that these molecules might contribute to thromboembolic events in both forms of IBD.
Lingua originaleEnglish
pagine (da-a)826-828
Numero di pagine3
Stato di pubblicazionePubblicato - 2008


  • Inflammatory bowel disease
  • PAI-1
  • TAFI
  • fibrinolisys


Entra nei temi di ricerca di 'PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system.'. Insieme formano una fingerprint unica.

Cita questo